NCT06987916View on ClinicalTrials.gov

Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

April 22, 2028

Study Completion Date

April 22, 2030

Conditions
B Cell Lymphoma
Interventions
BIOLOGICAL

ssCART-19

autologous T cells transduced with a lentiviral vector containing anti-CD19 CAR and small hairpin RNA to silence the IL-6 gene

Trial Locations (1)

200065

RECRUITING

Shanghai Tongji Hospital ( Tongji Hospital of Tongji University), Shanghai

All Listed Sponsors
lead

Shanghai Tongji Hospital, Tongji University School of Medicine

OTHER